Barclays Initiates Coverage of Sutro Biopharma (STRO) with Overweight Recommendation

Fintel reports that on May 28, 2026, Barclays initiated coverage of Sutro Biopharma (NasdaqGM:STRO) with a Overweight recommendation. Analyst Price Forecast Suggests 14.40% Upside https://www.nasdaq.com/articles/barclays-initiates-coverage-sutro-biopharma-stro-overweight-recommendation